ABVC BioPharma has secured Japanese patent protection for ABV-1504, its botanical-based Major Depressive Disorder treatment, extending intellectual property rights through 2040 and completing coverage across four major territories.
A comprehensive pipeline report reveals over 75 companies are developing innovative treatments for major depressive disorder, with several promising candidates advancing through Phase III trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.